Across TCGA pan-cancer cohorts, MIR181B1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MIR181B1 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher MIR181B1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR181B1 expression acts as an unfavorable survival marker.

THYM and COAD are the cancer types where MIR181B1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
COAD	OS	Median	All	0.001	0.871	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: MIR181B1 tumor-vs-normal RNA expression · all MIR181B1 data types